Immunolocalization of tissue plasminogen activator in the diabetic and nondiabetic retina and choroid.

Retinal capillary closure is a common finding in many patients with diabetic retinopathy. The cause of this capillary occlusion is unknown. Since occlusions in microthromboembolic disease can occur because of deficiencies in tissue plasminogen activator (tPA) and since systemic tPA decreases with an increasing duration of diabetes mellitus, the immunohistochemical localization of tPA in the retinas and choroids of diabetic and nondiabetic patients was investigated. The localization of tPA was confined to arteries and arterioles in peripheral retinas from nondiabetics. Both veins and arteries were positive in these choroids. Two of three noninsulin-dependent diabetics had normal levels of immunoreactivity in their retinas, and all had normal levels of immunolocalization in their choroids. All but 2 of the 12 insulin-dependent diabetic eyes (IDDM), however, had reduced levels of retinal tPA immunoreactivity which was most pronounced in their peripheral retinas. Seven eyes from patients with IDDM had no reaction product in their peripheral retinas. Two such eyes also had reduced tPA immunoreactivity in their choroidal vessels. Some tPA-positive vessels were observed in the central retinas of these eyes, but the number of positive vessels and amount of reaction product was greatly reduced compared with eyes from nondiabetic patients. These observations suggest that IDDM patients have reduced fibrinolytic activity in their retinas, which might predispose them to thromboembolic disease.

[1]  I. Nilsson,et al.  On fibrinolysis in diabetes mellitus. , 2009, Acta medica Scandinavica.

[2]  L V McIntire,et al.  Fluid flow stimulates tissue plasminogen activator secretion by cultured human endothelial cells. , 1989, Science.

[3]  E M Kohner,et al.  Long-term follow-up of retinal blood flow in diabetes using the blue light entoptic phenomenon. , 1989, The British journal of ophthalmology.

[4]  R. Tripathi,et al.  Distribution of tissue plasminogen activator in human and monkey eyes. An immunohistochemical study. , 1987, Ophthalmology.

[5]  B. Binder,et al.  Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies. , 1987, The Journal of laboratory and clinical medicine.

[6]  S. Pizzo,et al.  Defective release of tissue plasminogen activator in systemic and cutaneous vasculitis. , 1987, The American journal of medicine.

[7]  J. Hall,et al.  Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura. , 1986, The Journal of laboratory and clinical medicine.

[8]  A. Kjaeldgaard,et al.  In vitro stimulation of plasminogen activator release from vein walls by adrenaline. , 1986, Journal of clinical pathology.

[9]  A. Larsson,et al.  Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall. , 1985, Journal of clinical pathology.

[10]  F. Bachmann,et al.  Tissue Plasminogen Activator: Chemical and Physiological Aspects , 1984, Seminars in thrombosis and hemostasis.

[11]  D. Moscatelli,et al.  Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Little Alterations in blood elements in the pathogenesis of diabetic retinopathy. , 1981, Ophthalmology.

[13]  D. Rijken,et al.  Relationship between tissue plasminogen activator and the activators in blood and vascular wall. , 1980, Thrombosis research.

[14]  H. Keen,et al.  Haemostatic variables associated with diabetes and its complications. , 1979, British medical journal.

[15]  D. Loskutoff,et al.  Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[16]  V. N. Hegt Relations between Activation and Inhibition of Fibrinolysis in the Walls of Human Arteries and Veins , 1977, Thrombosis and Haemostasis.

[17]  I. Nilsson,et al.  Diabetic Retinopathy and the Fibrinolytic System , 1975, Diabetes.

[18]  M. Åberg,et al.  The plasminogen activator activity of arteries and veins in diabetes mellitus. , 1975, Thrombosis research.

[19]  A. Todd The histological localisation of fibrinolysin activator. , 1959, The Journal of pathology and bacteriology.

[20]  D. Collen,et al.  Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. , 1987, The Journal of laboratory and clinical medicine.

[21]  石崎 良太郎,et al.  ヒトTissue Plasminogen Activator(t-PA)の研究 I : 生産と精製法の検討 , 1986 .

[22]  D. Wagner,et al.  Von Willebrand protein binds to extracellular matrices independently of collagen. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[23]  P. Gaffney,et al.  Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. , 1980, Haemostasis.